Showing results (91-100 of 109) with videos related to

Sort By:
Pageof 11
Chest|April 8, 2009
Utility of [18F]2-fluoro-2-deoxyglucose-PET in sporadic and tuberous sclerosis-associated lymphangioleiomyomatosisLisa R Young, David N Franz, Preeti Nagarkatte, et al.
The New England Journal of Medicine|January 11, 2008
Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosisJohn J Bissler, Francis X McCormack, Lisa R Young, et al.
Epilepsia|October 25, 2021
Adjunctive everolimus therapy for tuberous sclerosis complex-associated refractory seizures: Results from the postextension phase of EXIST-3David N Franz, John A Lawson, Zuhal Yapici, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|July 23, 2002
Detection of Helicobacter pylori specific DNA in human atheromatous coronary arteries and its association to prior myocardial infarction and unstable anginaM Kowalski, W Rees, P C Konturek, et al.
Epilepsia|May 9, 2007
Surgical outcome in tuberous sclerosis complex: a multicenter surveyDeepak Madhavan, Sarah Schaffer, Alexei Yankovsky, et al.
Journal of Neurosurgery. Pediatrics|November 1, 2014
Long-term outcomes of resective epilepsy surgery after invasive presurgical evaluation in children with tuberous sclerosis complex and bilateral multiple lesionsRavindra Arya, Jeffrey R Tenney, Paul S Horn, et al.
The Lancet. Child & Adolescent Health|September 1, 2018
Adjunctive everolimus for children and adolescents with treatment-refractory seizures associated with tuberous sclerosis complex: post-hoc analysis of the phase 3 EXIST-3 trialPaolo Curatolo, David N Franz, John A Lawson, et al.
Neurology. Clinical Practice|December 20, 2018
Everolimus for treatment-refractory seizures in TSC: Extension of a randomized controlled trialDavid N Franz, John A Lawson, Zuhal Yapici, et al.
Lancet (London, England)|September 11, 2016
Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled studyJacqueline A French, John A Lawson, Zuhal Yapici, et al.
American Journal of Human Genetics|December 12, 2000
Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organsS L Dabora, S Jozwiak, D N Franz, et al.
Pageof 11